Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Predicine Inc. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across distinct examiners, meaning each examiner is responsible for one active application. However, both of these matters are contained within 1 distinct art unit, suggesting a shared technical classification for the company's biotechnology innovations. The busiest examiner for the company is HORLICK, KENNETH R, who is handling 1 busiest examiner pending action.
While the company must manage the perspectives of distinct examiners, the fact that they both operate within 1 distinct art unit may provide some consistency in the overall administrative environment. This distribution requires the applicant to address separate sets of examiner feedback while remaining within a single technical division of the patent office. The 1 busiest examiner pending action assigned to HORLICK, KENNETH R represents half of the 2 pending office actions total. This structure requires a strategy that balances individual examiner preferences with the unified standards of the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HORLICK, KENNETH R | 1 | 78.9% | +15.3% |
| SWITZER, JULIET CAROLINE | 1 | 42.4% | +54.0% |
| SCHLOOP, ALLISON ELIZABETH | 1 | 63.0% | +56.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18202423 | SYSTEMS AND METHODS FOR DETECTING GENETIC ALTERATIONS | SWITZER, JULIET CAROLINE | 50d overdue |
| 18406859 | SYSTEMS AND METHODS FOR COMBINED DETECTION OF GENETIC ALTERATIONS | HORLICK, KENNETH R | — |
| 18105113 | SYSTEMS AND METHODS FOR MONITORING OF CANCER USING MINIMAL RESIDUAL DISEASE ANALYSIS | SCHLOOP, ALLISON ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18202423 | SYSTEMS AND METHODS FOR DETECTING GENETIC ALTERATIONS | SWITZER, JULIET CAROLINE | 50d overdue |
| 18406859 | SYSTEMS AND METHODS FOR COMBINED DETECTION OF GENETIC ALTERATIONS | HORLICK, KENNETH R | — |
| 18105113 | SYSTEMS AND METHODS FOR MONITORING OF CANCER USING MINIMAL RESIDUAL DISEASE ANALYSIS | SCHLOOP, ALLISON ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18406859 | SYSTEMS AND METHODS FOR COMBINED DETECTION OF GENETIC ALTERATIONS | HORLICK, KENNETH R | — | §103§112 | Non-Final OA | — | Pending | Jan 08, 2024 |
| 18202423 | SYSTEMS AND METHODS FOR DETECTING GENETIC ALTERATIONS | SWITZER, JULIET CAROLINE | 1682 | §101§103Other | Non-Final OA | 50d overdue | Pending | May 26, 2023 |
| 18105113 | SYSTEMS AND METHODS FOR MONITORING OF CANCER USING MINIMAL RESIDUAL DISEASE ANALYSIS | SCHLOOP, ALLISON ELIZABETH | 1683 | §101§103§112DP | Non-Final OA | — | Pending | Feb 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial